SUMMARY:

COPD exacerbation is characterized by worsening of cardinal symptoms, i.e. increased dyspnea, cough, and/or sputum purulence or production/volume within the span of 14 days. Classification is via Gold’s Classification (see Diagnosis and Management of Stable COPD in ‘Related Topics’ below). Exacerbations involve increased airway inflammation, increased mucus production, and increased gas trapping. They are commonly precipitated by respiratory tract infections, although there can be many triggers. Exacerbations contribute to disease progression and are associated with increased mortality and morbidity.

Diagnosis of COPD

• Screening spirometry for the general population is not recommended
• Cardinal symptoms of COPD
  • Persistent dyspnea (typically progressive over time and worse with exercise)
  • Chronic cough (may be intermittent +/- sputum production)
  • Wheezing and chest tightness
  • Fatigue
  • Recurrent lower respiratory tract infections
• More likely with the following history of risk factors:
  • Tobacco smoke exposure
  • Exposure to smoke from home cooking and heating fuels, occupational dusts, vapors, fumes, gases and other chemical exposures
  • Medical comorbidities including genetic factors, developmental abnormalities, low birthweight, prematurity, childhood respiratory infections, etc.
• Differential diagnosis:
  • COPD – Symptoms are slowly progressive AND typically present in patients with the risk factors as above
  • Asthma – Symptoms are typically worse at night/early morning, occurs more in children, often with family history of asthma, often associated with allergies/rhinitis/eczema
  • Congestive heart failure – Chest X-ray will show dilated heart and pulmonary edema. Pulmonary function tests won’t show airflow obstruction
  • Bronchiectasis – Large volumes of purulent sputum production, commonly associated with bacterial infection, and chest X-ray will show bronchial dilation
  • Tuberculosis – Chest X-ray will show lung infiltrate, TB testing is positive, risk factors for TB infection
• Spirometry
  • Pre-bronchodilator FEV1/FVC <0.7
  • AND Post-bronchodilator FEV1/FVC>0.7 confirms non-reversible airflow obstruction, which is characteristic of COPD (as opposed to asthma which is reversible)

Diagnosis of COPD Exacerbation

• Exacerbation is an acute event during which symptoms worsen for a few days (up to 14 days)
  • Increase dyspnea and/or cough
  • +/-  associated tachypnea and/or tachycardia
  • +/-  increase in sputum purulence and/or volume
  • Can be associated with increased local and systemic inflammation (infection, pollution or other insult to lungs)
• Severity of exacerbation classified as follows:
  • Mild disease: Dyspnea VAS < 5 | RR < 24 | HR <95 | Resting SpO2 ≥ 92% on RA or usual O2 supplementation AND change ≤ 3% | CRP < 10 mg/L (if obtained)
  • Moderate (needs 3 of 5): Dyspnea VAS ≥ 5 | RR ≥ 24 | HR ≥95 | Resting SpO2 < 92% on RA or usual O2 supplementation AND change > 3% | CRP ≥ 10 mg/L | ABG with hypoxemia or hypercarbia
  • Severe: Dyspnea, RR, HR, SpO2 and CRP same as moderate but ABG with hypoxemia (PaO2 ≤ 60 mmHg) and/or hypercapnia and acidosis (PaCO2 > 45 mmHg and pH <7.35)

Treatment

Determine if Patient Can Be Treated Outpatient or Requires Hospitalization

• Outpatient criteria:
  • Mild exacerbation event
  • Minimal comorbidities
  • Patient is cooperative
  • Patient has good home support

• Inpatient criteria:
  • Symptoms and signs of respiratory failure such as increased RR, use of accessory respiratory muscles, worsening hypoxemia and/or hypercarbia and acute changes in mental status
  • Failure of exacerbation to respond to initial medical management
  • Presence of serious medical comorbidities
  • Insufficient home support

Initial Bronchodilators for Every Patient

• Start low and increase doses and/or frequency of short-acting bronchodilators as-needed (via pressured metered dose inhaler with spacer or nebulizer)
  • One dose of nebulized medication every hour for 2-3 doses or use a pMDI one or two puffs every one hour for two or three doses and then every 2-4 hours based on the patient’s response
• Combine SABA with muscarinic antagonist medications
• Consider starting on long-acting bronchodilators once stabilized

Muscarinic Antagonists

• Ipratropium bromide, a short acting muscarinic antagonist, often used in combination with SABA, dosing as above.

Systemic Corticosteroids

• Improve lung function (FEV1), oxygenation and shorten recovery and hospitalization time
• Recommended course is oral prednisone 40 mg for 5 days
  • Longer courses of steroids associated with increased risk of pneumonia and mortality
  • Outpatient: Recommended only in those who present with breathlessness that affect daily activities
  •  Inpatient: Always get a course of systemic steroids

Note: European Respiratory Society/American Thoracic Society suggest a course of oral corticosteroids for 9–14 days in outpatients with COPD exacerbations in contrast to the GOLD guidelines

Antibiotics

• COPD exacerbations can be caused by viral or bacterial infections.  Antibiotics should be reserved for patients who have evidence of bacterial infection:
  • Have sputum purulence AND one of the following: increased dyspnea, fever, or sputum volume.
  • Positive prior sputum culture during previous exacerbation
  • Not recommended to use procalcitonin as a biomarker for bacterial infection
  • Require ICU level care or mechanical ventilation
• Benefit if antibiotics are administered in the first 2 days of hospitalization
• Use in outpatient management is less clear, but there is evidence of benefit in patients who are moderately or severely ill with symptoms that include cough and sputum purulence
• Obtaining a sputum culture is recommended for patients with recurrent exacerbations to guide antibiotic treatment
• For choice of antibiotic, local bacterial resistance patterns should be considered
• Initial empiric treatment is an aminopenicillin with clavulanic acid, a macrolide, or a tetracycline
• Duration 5-7 days for hospitalized patients | No more than 5 days for outpatients

Prevention

• Smoking cessation
• Ensure vaccines up to date (influenza, RSV, pneumonia)  
• Use of LABA+LAMA+ICS fixed combination treatment (triple therapy inhalers)
• Pulmonary rehab referral within 4 weeks of hospital discharge
• Consider prophylactic antibiotics for one year if a patient is prone to exacerbations. Note no evidence of benefit after one year:
  • Azithromycin 250mg per day or 500mg three times a week
  • Erythromycin 250mg BID

Primary Sources – Learn More:

GOLD: 2026 Report

European Respiratory Society/American Thoracic Society: Management of COPD Exacerbations (2017)